Cardiac Biotech Solutions, Inc. (CBSC)
0.0356
0.00 (0.00%)
USD |
OTCM |
Sep 04, 16:00
Cardiac Biotech Solutions Research and Development Expense (Quarterly) : 0.0132M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.0132M |
| March 31, 2026 | |
| December 31, 2025 | 0.028M |
| September 30, 2025 | 0.0019M |
| June 30, 2025 | 0.0353M |
| March 31, 2025 | 0.0944M |
| December 31, 2024 | 0.0232M |
| September 30, 2024 | 0.0334M |
| June 30, 2024 | 0.0222M |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | 0.1647M |
| December 31, 2022 | 0.1003M |
| September 30, 2022 | 0.0914M |
| June 30, 2022 | 0.1286M |
| March 31, 2022 | |
| December 31, 2021 | 0.00 |
| September 30, 2021 |
| Date | Value |
|---|---|
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Vyome Holdings, Inc. | 0.5067M |
| Abbott Laboratories | 892.00M |
| AngioDynamics, Inc. | 8.178M |
| Alphatec Holdings, Inc. | 18.17M |
| AtriCure, Inc. | 25.67M |